Myelin basic protein (MBP) is one of the most abundant proteins in the human brain. Active immunization with MBP induces experimental autoimmune encephalomyelitis, and anti-MBP antibodies have been repeatedly described in MS.
with rat brain lysate and samples run on sodium dodecyl sulfate (SDS) gels. Bands were analyzed with mass spectrometry, 5 and data were analyzed as described, 6 matching MBP only. Double immunolabeling showed exact co-localization of patient antibody with a commercial anti-MBP antibody (figure, D-F). In contrast to the commercial antibody, the patient's IgA did not bind to rat brain lysate in denaturing Western blots (not shown), suggesting that they recognize the natural epitope conformation. Direct proof for the target antigen was obtained using MBP knockout mice in which the antibody binding was completely lost (figure, G-J).
Discussion
We report the case of a patient with MS with rapidly progressing cognitive decline having high-level autoantibodies against conformational MBP. Previous studies using denatured epitopes in enzyme-linked immunosorbent assay and Western blots could not establish a clear link between MBP antibodies and disease, 2,3 potentially because they overlooked specific binding to the conformational epitope. This first report of MBP autoantibodies against native MBP revives the discussion of whether such antibodies might be related to a subgroup of MS patients, convey pathology, or serve as a biomarker for progression or cognitive symptoms.
Similar to MBP, the pathogenic role of MOG antibodies has been debated intensely. Only more recent studies focusing on antibody interactions with native MOG could convincingly demonstrate their pathogenic potential. 7 For example, such MOG antibodies were present in a subgroup of patients with severe MS. The clinical improvement with immunotherapy in our patient paralleled the disappearance of antibody titers, suggesting that the antibodies may have contributed to the disease. IgA antibody transfer into animals should be an important future experimental step to confirm pathogenicity.
It is unclear at present whether autoantibodies against native MBP are also detected in a subgroup of patients with MS. We did not find a similar immunofluorescence pattern using the serum and CSF of 352 consecutive patients with suspected encephalitis (including 46 patients with MS) and serum of 82 healthy controls, suggesting that-similar to MOG antibodies-the specific myelin staining observed in the present patient is rare. Prospective studies using established cohorts with MS and clinically isolated syndrome (CIS) should therefore be screened systematically to determine the frequency of native MBPtargeting autoantibodies, the association with clinical phenotypes, CIS conversion to MS, relapses, and disease progression.
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